Prostate Cancer Therapeutics Market - Global
Industry Analysis, Size, Share, Growth, Trends Single User
and Forecast 2015 - 2023
USD 4315.5
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
www.transparencymarketresearch.com
sales@transparencymarketresearch.com
License:
Flat 10% Discount!!
Free Customization as per your requirement
You will get Custom Report at Syndicated Report
price
Report will be delivered with in 15-20 working days
Request Sample
Buy Now
REPORT DESCRIPTION
Prostate cancer is among serious health issue among men has large socioeconomic impact on the society. It is the most common cancer
diagnosed among men in developed regions, while it is sixth most common cancer diagnosed in less developed nations. Routine screening, early
diagnosis, and recent treatment options have enabled increased survival of prostate cancer patients. Prostate cancer is an abnormal and
uncontrolled growth of cells in prostate gland of a male individual. Approximately 75% of prostate cancers are developed sporadically in which
genetic changes occur after birth. Although, cause prostate cancer is largely unknown, some of the prime factors associated with the disease
include obesity, overweight and past history of certain cancers. A person with cardiovascular disease is more prone to advanced metastatic
cancer.
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/prostate-cancer-therapeutics-market.html
Androgens have significant role in the pathogenesis of prostate cancer and therefore androgen-deprivation therapy (ADT) was found to be most
useful in treating of locally advanced or metastatic prostate cancer. Presently, the prostate cancer therapeutics market is driven by major drugs
such as Zytiga (Johnson & Johnson), Xtandi (Astellas Pharma, Inc. / Medivation, Inc.), Provenge (Dendreon Corporation), Jevtana (Sanofi) and
Xofigo (Bayer Healthcare...